Table 3.
The MR of TAM and its metabolites among different CYP2D6 polymorphisms
| CYP2D6 | n | MR (TAM-NDMT) | MR (NDMT-END) | MR (TAM-4OHT) | MR (4OHT-END) |
|---|---|---|---|---|---|
| Genotype | 133 | p=0.000* | p=0.078 | p=0.094 | p=0.470 |
| CYP2D6*1/*1 | 13 | 0.51 (0.23) | 11.72 (22.57) | 61.05 (52.86) | 0.08 (0.33) |
| CYP2D6*1/*10 | 21 | 0.38 (0.11) | 15.19 (20.04) | 56.18 (60.29) | 0.08 (0.16) |
| CYP2D6*10/*10 | 72 | 0.34 (0.09) | 23.57 (25.79) | 77.07 (49.80) | 0.10 (0.09) |
| CYP2D6*2/*2 | 5 | 0.32 (0.09) | 16.84 (13.87) | 63.50 (52.33) | 0.08 (0.10) |
| CYP2D6*2/*10 | 13 | 0.34 (0.10) | 19.53 (20.39) | 60.66 (18.32) | 0.11 (0.06) |
| CYP2D6*1/*2 | 3 | 0.40 (0.00) | 10.96 (0.00) | 92.99 (0.00) | 0.04 (0.00) |
| CYP2D6*4/*4 | 2 | 0.30 (0.00) | 21.56 (0.00) | 40.48 (0.00) | 0.17 (0.00) |
| CYP2D6*4/*10 | 4 | 0.27 (0.10) | 39.96 (33.71) | 69.34 (119.84) | 0.15 (0.30) |
| Phenotype | 133 | p=0.013* | p=0.014* | p=0.017* | p=0.594 |
| EM | 55 | 0.10 (0.03) | 15.19 (15.55) | 61.05 (34.92) | 0.08 (0.13) |
| IM | 76 | 0.09 (0.02) | 24.06 (26.15) | 76.80 (49.8) | 0.10 (0.09) |
| PM | 2 | 0.08 (0.00) | 21.56 (0.00) | 40.48 (0.00) | 0.17 (0.00) |
Note: The concentrations of TAM and its metabolites are presented as median (interquartile range). p=p value from Kruskal–Wallis test,
*
p<0.05.
Abbreviations: 4OHT, 4-hydroxytamoxifen; EM, extensive metabolizer; END, endoxifen; IM, intermediate metabolizer; MR, metabolic ratios; NDMT, N-desmethyl tamoxifen; PM, poor metabolizer; TAM, tamoxifen.